Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01243073 · ClinicalTrials.gov registry record · Phase 2
Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera
A Phase 2 study, sponsored by Geron Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01243073 is a Phase 2 study that has completed, run by Geron Corporation. The registered enrollment target is 20 participants.
The verdict
NCT01243073, a Phase 2 study, has completed, sponsored by Geron Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a phase II open-label study of single agent imetelstat in patients with essential thrombocytopenia or with polycythemia vera who have failed or are intolerant to at least one prior therapy, or who refuse standard therapy.
Interventions
- DRUG Imetelstat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-12 |
| Est. Completion | 2015-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01243073
The ClinicalTrials.gov registry entry for NCT01243073 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Geron Corporation, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Imetelstat is the first listed.
NCT01243073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01243073 about?
NCT01243073 is a clinical study titled "Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera". This is a phase II open-label study of single agent imetelstat in patients with essential thrombocytopenia or with polycythemia vera who have failed or are intolerant to at least one prior therapy, or who refuse standard therapy.
What is the current status of trial NCT01243073?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2010-12. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01243073?
The interventions under investigation include: Imetelstat (DRUG).
Who is sponsoring clinical trial NCT01243073?
This trial is sponsored by Geron Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.